

GLAXOSMITHKLINE PLC
Form 6-K
April 21, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 21 April 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')
Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley
 b) Position/status Chief Executive Officer
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£16.47	910.450
	£16.47	1,756.522
	£16.47	2,998.638

- d) Aggregated information

Aggregated volume Price

5,665.610
£16.47

- e) Date of the transaction 2017-04-18
f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
b) Position/status President, Global Manufacturing & Supply

- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

- c) Price(s) and volume(s)
Price(s) Volume(s)
£16.47 1,367.102
£16.47 1,752.027

Aggregated information

- d) Aggregated volume Price 3,119.129
£16.47

- e) Date of the transaction 2017-04-18

- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr L Debruyne
- b) Position/status President, Global Vaccines
- c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £16.47 | 349.698 |
| £16.47 | 440.757 |
- d) Aggregated information
- | Aggregated volume | Price |
|-------------------|--------|
| 790.455 | £16.47 |
- e) Date of the transaction 2017-04-18
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr S Dingemans

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) Position/status Chief Financial Officer
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- Ordinary shares of 25 pence each ('Ordinary Shares')
- ISIN: GB0009252882
- a) Description of the financial instrument

- b) Nature of the transaction
- Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £16.47 | 2,973.255 |
| £16.47 | 3,220.155 |

- Aggregated information
- d) Aggregated volume Price
- | | |
|-----------|--------|
| 6,193.410 | £16.47 |
|-----------|--------|
- e) Date of the transaction 2017-04-18
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr N Hirons
- b) Position/status SVP, Global Ethics & Compliance
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£16.47	662.840
	£16.47	722.300

- d) Aggregated information

Aggregated volume Price 1,385.140
 £16.47

- e) Date of the transaction 2017-04-18

- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S A Hussain
 b) Position/status President, Global Pharmaceuticals

- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.	
	Price(s)	Volume(s)
c) Price(s) and volume(s)	£16.47	3,107.069
	£16.47	3,502.071

d) Aggregated information	
Aggregated volume	6,609.140
Price	£16.47
e) Date of the transaction	2017-04-18
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr D S Redfern
 - b) Position/status Chief Strategy Officer
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument

	Ordinary shares of 25 pence each ('Ordinary Shares')
	ISIN: GB0009252882
 - b) Nature of the transaction

	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April
--	--

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

2017 on Ordinary Shares held
in the Company's 2009
Performance Share Plan.

Price(s)	Volume(s)
£16.47	1,087.465

c) Price(s) and
volume(s)

£16.47	1,269.488
--------	-----------

Aggregated information

d) Aggregated volume Price

2,356.953
£16.47

e) Date of the transaction

2017-04-18

f) Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas

b) Position/status SVP, HR

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

Ordinary shares of 25 pence
each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction

Increase in notional interest
in Ordinary Shares following
the re-investment of
dividends paid to
shareholders on 13 April
2017 on Ordinary Shares held
in the Company's 2009
Performance Share Plan.

Price(s)	Volume(s)
£16.47	1,449.959

c) Price(s) and
volume(s)

£16.47	1,597.807
--------	-----------

Aggregated information	
d) Aggregated volume Price	3,047.766 £16.47
e) Date of the transaction	2017-04-18
f) Place of the transaction	n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr P C Thomson
- b) Position/status President, Global Affairs
Initial
- c) notification/ Initial notification
amendment

2. market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

- c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.47	838.910
£16.47	919.292

- d) Aggregated information

Aggregated
 volume Price 1,758.202
 £16.47

- e) Date of the transaction 2017-04-18
 Place of the
 f) transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr P J T Vallance
 b) Position/status President, R&D
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

- c) Price(s) and volume(s)
 Price(s) Volume(s)
 £16.47 3,015.919
 £16.47 3,720.939

d) Aggregated information

Aggregated volume Price

6,736.858
 £16.47

- e) Date of the transaction 2017-04-18
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs V A Whyte
 b) Position/status Company Secretary
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| £16.47 | 175.499 |
| £16.47 | 185.700 |

- d) Aggregated information
- Aggregated volume Price

361.199
 £16.47

- e) Date of the transaction 2017-04-18
 f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 21, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc